Roche announced the launch of the IDH1 R132H , MRQ-67, Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer. "A patient’s IDH1 status helps determine eligibility for clinical trials, which offers more treatment options, and may one day lead to potential targeted therapies for people fighting brain cancer," said Matt Sause, CEO of Roche Diagnostics. Immunohistochemistry is recommended by all major glioma practice guidelines for determining IDH1 R132H and ATRX mutation status. The IDH1 assay can also detect the IDH1 R132H mutation in acute myeloid leukaemia. Roche’s IDH1 and ATRX assays are optimised and fully-automated on the BenchMark series of instruments. The two tests are now available in the US. They will likely be available in other non-CE markets later this year and in countries that accept the CE mark in 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
- iBio downgraded to Market Perform at JMP on CDMO and IBIO-101 questions
- Hookipa Pharma achieves $10M milestone payment under Roche collaboration
- Genentech reports both BALATON, COMINO studies meet primary endpoint
- New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
